

**Clinical Utility of Coronary Calcium Scoring in
Diabetic patients with Normal or Mild Ischemia in
Myocardial Perfusion Scintigraphy.**

Thesis submitted for partial fulfillment of MD Degree

By:

Dr. Mohammed Abdel Aziz Attia

Supervised By:

Dr.Ahmed Ibrahim Nassar

Professor of cardiology Ain Shams University

Dr.Ahmed Abd El-Rahman Sharaf El-din

Professor of cardiology Ain Shams University

Dr. Amr Adel Elsayed

Professor of cardiology Ain Shams University

Dr.Rania Sameer Ahmed

Lecturer of cardiology Ain Shams University

Dr.Amr Dawood Mohamed El-Guindy

Consultant of cardiology police hospital Agoza

Faculty of Medicine

Ain shams University 2010

قال تعالى :-

وقل رب زدني علما

صدق الله العظيم

List of contents

	<i>Page</i>
· Introduction	1
· Aim of the work	2
· Review of literature	
o Diabetes mellitus & CHD	3
o Vascular calcification	26
o Coronary calcium scoring	47

· Patients and methods	85
· Results	102
· Discussion	150
· Conclusion	164
· Recommendations	167
· Summary	170
· References	174
· Arabic summary	205

List of tables

Tab. No.	Title	Page No.
----------	-------	----------

Table (1): Absolute Risk Categories According to National Cholesterol Education Program Update, 2004.....(7)

Table (2a): Demographic data, risk factors among patients with normal myocardial perfusion scintigraphy and with mild ischemia.....(106)

Table (2b): Clinical & stress test data in patients with normal myocardial perfusion scintigraphy and with mild ischemia(109)

Table (3): Age distribution among different groups.....(113)

Table (4):(Post Hoc Test) showing multiple comparisons for detection of least significant difference among groups.....(114)

Table (5): Gender and risk factors among different groups.....(115)

Table (6): Resting ECG among different groups.....(118)

Table (7): Clinical data among different groups.....(121)

Table (8): Stress test among different groups.....(122)

Table(9): MPS result among different groups(125)

Table (10): CA result among different groups.....(126)

Table (11): PCI & CABG performed in different groups.....(127)

Table (12): The sensitivity, specificity, PPV, NPV and overall accuracy of CAC.....(131)

Table (13): MPS results in relation to coronary angiograms...(133)

Table (14): Stress test in relation to coronary angiogram..... (133)

Table (15): The sensitivity, specificity, PPV, NPV and overall

accuracy of CAC, MPS and Stress test.....	(134)
Table (16): Follow up regarding symptoms and hard events...	(137)
Table (17): Cox regression analysis for events.....	(138)

List of figures

Figure 1. The metabolic abnormalities that characterize diabetes. (10)

Figure 2. Hyperglycemia and endothelium derived vasoactive substances. (11)

Figure 3. Platelet function and plasma coagulation factors are altered in diabetes, favoring platelet aggregation and a propensity for thrombosis. (24)

Figure 4. Schematic diagram depicting parallel mechanisms in soft tissue versus atherosclerotic and non atherosclerotic vascular calcification. (29)

Figure 5. Types of Vascular Calcification. (35)

Figure 6. Representation of the coronary anatomy in relation to the inter-ventricular & atrio-ventricular planes.....(51)

Figure 7. Meta-analysis on the prognostic value of CAC scores. (63)

Figure 8. Annual rates of coronary heart disease (CHD) death or nonfatal myocardial infarction (MI) by coronary artery calcium score. (65)

Figure 9. Overall annual cardiac death or MI rate by tertiles of the Agatston score in patients with an intermediate Framingham risk score. (67)

Figure 10. The frequency of an ischemic MPS by CCS in type 2 DM (70)

Figure 11. Event risk is for asymptomatic individuals, symptomatic individuals with elevated CAC scores have considerably higher event rates. (74)

Figure 12: MSCT coronary angiography (81)

Figure 13: Multislice 4-detector row CT coronary angiography in a 72-years old symptomatic male patient (82)

Figure 14.

Clinical “work-up” algorithm for Intermediate Framingham Risk Score patients as well as for high FRS,diabetics, those with the metabolic syndrome, or with a family history of premature Coronary Heart Disease (83)

Figure 15: General Electric Maxi camera 400 AC (91)

Figure 16 General Electric Lightspeed QXI 4 Slice (95)

Figure 17 General Electric AdvantX - LFX . (97)

Figure.18: Gender distribution in the study population. (102)

Figure 19 Distribution of DM among the study population. (103)

Figure 20 Risk factor distribution in the study population(103)

Figure 21 MPI results in the study population. (104)

Figure 22 showing age distribution in all groups (113)

Figure 23 Risk factor distribution in the study population
(116)

Figure 24 Clinical data among different groups (122)

Figure 25 Stress test result among different groups (123)

Figure 26 MPS result distribution among different groups
(126)

Figure 27 Angiographic results among different groups
(127)

Figure 28a Percentage of patients performed PCI & CABG in relation to the presence of coronary artery stenosis among different groups (128)

Figure 28b CA, stress test and MPS result distribution among different groups. (128)

Figure 29: The sensitivity & specificity of CAC in relation to coronary angiography (per vessel basis). (131)

Figure 30: The sensitivity & specificity of CAC, MPI & stress test . (135)

Figure 31a: MPS in case No 1. (140)

Figure 31b: RAO-Caudal view showing tight LAD stenosis and ectatic CX (141)

Figure 31c: RAO-Cranial view showing wire in the LAD and balloon couldn't pass the tight LAD stenosis. (141)

Figure 32a: MPS in case No 2. (143)

Figure 32b: LAO view showing RCA stenosis (144)

Figure 32c: RAO-Cranial view showing atherosclerotic changes in LAD,CX & diagonal vessels (144)

Figure 32d: showing post stenting in RCA. (144)


Figure 32 e: Acute stent thrombosis in RCA stent (145)


<u>Figure 32 f:</u> Recanalized RCA	(145)
<u>Figure 33a:</u> MPS in case No 3.	(147)
<u>Figure 33b:</u> Lao 90 view showing LAD stenosis	(148)
<u>Figure 33c:</u> Post stenting in LAD.	(148)
<u>Figure 33d:</u> LAD supplied from RCA collaterals	(149)
<u>Figure 33e:</u> Instent restenosis in LAD	(149)

List of abbreviations

AGEs:	· Advanced glycation end products.
CAC:	· Coronary artery calcification.
CAD:	· Coronary artery disease.
Cbfa1:	· Core binding factor alpha 1.
CHD:	· Coronary heart disease.
CKD :	· Chronic kidney disease.
CS:	· Calcium scores.
CT :	· Computed tomography.

EBCT, EBT:	· Electron beam computed tomography.
eNOS:	· Endothelial Nitric oxide synthase.
HDLc:	· High density lipoprotein cholesterol.
HsCRP:	· High sensitivity C reactive protein.
HU:	· Hounsfield units.
LDLc :	· Low density lipoprotein cholesterol.
MPS:	· Myocardial perfusion single-photon emission computed tomography.
MSCT:	· Multislice spiral computed tomography.
NAD:	· Nicotinamide adenine dinucleotide.
NADPH:	· Nicotinamide adenine dinucleotide phosphate oxidase.
NCEP:	· National cholesterol education program
NF-KB:	· Nuclear factor kappa beta.
NO:	· Nitric oxide
OPN:	· Osteopontin.
PGI2:	· Prostacyclin.
RAGE :	· Receptor for advanced glycation end products.
RANKL:	· Receptor activator of nuclear factor kappa B.
SDS:	· Summed difference score.
SSS:	· Summed stress score.
TC :	· Total cholesterol.





Introduction
& Aim of work

Review of literature